Abstract:Background and aims: Several studies have shown that expression of hepatic fibroblast growth factor 21 (FGF21) can be stimulated by glucagon-like peptide 1 (GLP-1)-based diabetes drugs. As GLP-1 receptor (GLP-1R) is unlikely to be expressed in hepatocytes, we aimed to compare such stimulation in mice and in mouse hepatocytes, determine the involvement of GLP-1R, and clarify whether FGF21 mediates certain functions of the GLP-1R agonist liraglutide. Approach and results: Liver FGF21 expression was assessed in mice receiving a daily liraglutide injection for 3 days or in mouse primary hepatocytes (MPHs) undergoing direct liraglutide treatment. The effects of liraglutide on metabolic improvement and FGF21 expression were then assessed in high-fat diet (HFD)-fed mice and compared with the effects of the dipeptidyl-peptidase 4 inhibitor sitagliptin. Animal studies were also performed in Glp1r-/- mice and liver-specific FGF21-knockout (lFgf21-KO) mice. In wild-type mouse liver that underwent RNA sequencing and quantitative reverse-transcription PCR, we observed liraglutide-stimulated hepatic Fgf21 expression and a lack of Glp1r expression. In MPHs, liraglutide did not stimulate Fgf21. In mice with HFD-induced obesity, liraglutide or sitagliptin treatment reduced plasma triglyceride levels, whereas their effect on reducing body-weight gain was different. Importantly, increased hepatic FGF21 expression was observed in liraglutide-treated mice but was not observed in sitagliptin-treated mice. In HFD-fed Glp1r-/- mice, liraglutide showed no beneficial effects and could not stimulate Fgf21 expression. In lFgf21-KO mice undergoing dietary challenge, the body-weight-gain attenuation and lipid homeostatic effects of liraglutide were lost or significantly reduced. Conclusions: We suggest that liraglutide-stimulated hepatic Fgf21 expression may require GLP-1R to be expressed in extrahepatic organs. Importantly, we revealed that hepatic FGF21 is required for liraglutide to lower body weight and improve hepatic lipid homeostasis. These observations advanced our mechanistic understanding of the function of GLP-1-based drugs in NAFLD.

Liver-derived Fibroblast Growth Factor 21 Mediates Effects of Glucagon-Like Peptide-1 in Attenuating Hepatic Glucose Output

FGF21 Normalizes Plasma Glucose in Mouse Models of Type 1 Diabetes and Insulin Receptor Dysfunction

Hepatic Fibroblast Growth Factor 21 Is Involved in Mediating Functions of Liraglutide in Mice With Dietary Challenge

Fibroblast growth factor 21 regulates glucose metabolism in part by reducing renal glucose reabsorption.

FGF21 Suppresses Hepatic Glucose Production Through the Activation of Atypical Protein Kinase Cι/λ.

Liver Plays a Major Role in FGF-21 Mediated Glucose Homeostasis.

Fibroblast Growth Factor-21 Mediates Hepatic Glucose Metabolism of Type 1 Diabetes Model and Its Mechanism

Liver Fibroblast Growth Factor 21 (FGF21) is Required for the Full Anorectic Effect of the Glucagon-Like Peptide-1 Receptor Agonist Liraglutide in Male Mice fed High Carbohydrate Diets

Fibroblast Growth Factor 21 Stimulates Pancreatic Islet Autophagy via Inhibition of AMPK-mTOR Signaling

Fibroblast Growth Factor 21 Improves Glucose Homeostasis Partially Via Down-Regulation of Na+-d-glucose Cotransporter SGLT1 in the Small Intestine.

Exenatide Treatment Decreases Fasting Fibroblast Growth Factor 21 Levels in Patients with Newly Diagnosed Type 2 Diabetes Mellitus.

Fibroblast growth factor 21 improves hepatic insulin sensitivity by inhibiting mammalian target of rapamycin complex 1 in mice

Fibroblast Growth Factor 21 Reverses Hepatic Steatosis, Increases Energy Expenditure, and Improves Insulin Sensitivity in Diet-Induced Obese Mice

Pancreatic fibroblast growth factor 21 protects against type 2 diabetes in mice by promoting insulin expression and secretion in a PI3K/Akt signaling‐dependent manner

Cellular Mechanisms by Which Fgf21 Improves Insulin Sensitivity in Male Mice

Effect and underlying mechanism of liraglutide on fibroblast growth factor-21 production in mouse islet β cells

The role of the glucagon‐FGF21 axis in improving beta cell function during glucose intolerance and SGLT2 inhibition

Fibroblast Growth Factor-21 is Required for Weight Loss Induced by the Glucagon-like Peptide-1 Receptor Agonist Liraglutide in Male Mice fed High Carbohydrate Diets

Fibroblast growth factor 21 protects the liver from apoptosis in a type 1 diabetes mouse model via regulating L-lactate homeostasis

Fibroblast growth factor 21 protects against lipotoxicity-induced pancreatic β-cell dysfunction via regulation of AMPK signaling and lipid metabolism.

Mechanisms of the Role of Fibroblast Growth Factor 21 in Attenuating Insulin Resistance